MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study-Reference-Cited by-同舟云学术

MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study

Published:1998-06 Issue:1 Volume:86 Page:20-29
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

McManus Carrie,Berman Joan W,Brett Francesca M,Staunton Hugh,Farrell Michael,Brosnan Celia F

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,Immunology,Immunology and Allergy

Reference36 articles.

1. Chemokines: leukocyte recruitment and activation cytokines;Adams;Lancet,1997

2. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines;Baggiolini;Adv. Immunol.,1994

3. Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor (TNF) or antibody to the 55-kDa TNF receptor;Barna;J. Neuroimmunol.,1994

4. Localization of MCP-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat;Berman;J. Immunol.,1996

5. Mechanisms of immune injury in multiple sclerosis;Brosnan;Brain Pathol.,1996

Cited by 328 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of serum MIP-1β and MCP-2 levels in major depressive disorder: A case-control study;PLOS ONE;2024-06-18

2. Blood‐based inflammatory protein biomarker panel for the prediction of relapse and severity in patients with neuromyelitis optica spectrum disorder: A prospective cohort study;CNS Neuroscience & Therapeutics;2024-06

3. Evaluating CXCL12 for Effects on Reactive Gene Expression in Primary Astrocytes;Journal of Molecular Neuroscience;2024-05-28

4. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial;Stem Cell Research & Therapy;2024-05-23

5. Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis;Journal of Neuroimmunology;2024-05